What is Byetta? Are There Georgia Byetta Lawsuits?

Georgia Byetta LawsuitByetta, approved in April 2005 by the U.S. Food and Drug Administration, was initially intended to help individuals previously diagnosed with type 2 diabetes to manage their condition and fluctuating blood sugar levels. While many have successfully taken Byetta and reported little or no complications, clinical trials and adverse event reports have suggested a relationship between Byetta and pancreatic and thyroid cancers as well as kidney failure.

If you or someone you love has been diagnosed with a serious or life-threatening complication such as cancer or renal impairment, consider filing a Georgia Byetta lawsuit to seek compensation for your injuries. You may be entitled to hold the manufacturer accountable and file for pain and suffering, lost wages and medical expenses you may have incurred as a result of your condition.

What is Byetta?

Byetta falls into a group of medications known as incretin mimetics. These drugs work to imitate the function of the hormone incretin in patients’ bodies by increasing insulin production in the pancreas. Amylin Pharmaceuticals, the manufacturer of Byetta, allegedly stated that patients using Byetta could better manage type 2 diabetes as their bodies were able to make better use of the insulin.

Still, plaintiffs filing Byetta lawsuits allege that Amylin grossed over $700 million in Byetta sales between the drug’s introduction and 2008. Additionally, plaintiffs allege that the manufacturer used aggressive marketing tactics to reach these sales figures although the potentially dangerous side effects of the medication had not yet become apparent. Since its introduction, over seven million prescriptions have been filled for the drug, according to court records.

Is Byetta Safe for Patients?

According to adverse event reports and results of clinical trials, those taking Byetta may be six times more likely to suffer from pancreatic cancer than those who took other medications to help manage their condition. A February 2013 study also reported that Byetta users were twice as likely to need hospitalization for pancreatitis as those who chose other drugs for type 2 diabetes. If you have been injured, a Georgia Byetta lawsuit can help you to receive the financial compensation to which you are entitled.

Have you or a loved one suffered from one or more of the following side effects? You may be entitled to file a Georgia Byetta lawsuit and claim damages such as pain and suffering, medical expenses, lost wages and loss of earning capacity. Some of the more serious side effects include:

  • Kidney damage or renal impairment
  • Chest pain
  • Headaches
  • Nausea
  • Vomiting
  • Hypersensitivity
  • Immunogenicity
  • Hypoglycemia
  • Allergic reactions

 

Current Byetta Lawsuits

Since the number of plaintiffs filing lawsuits across the country is increasing, the decision was recently made to consolidate all claims pertaining to incretin mimetics including Byetta, Janumet, Januvia and Victoza into a single multidistrict litigation (MDL). The proceeding will appear in front of the U.S. District Court, Southern District of California.

According to court records, 60 claims were filed as of September 2013. That number increased to over 150 claims one month later, in October 2013. Attorneys assert that the possibility of additional plaintiffs coming forward is likely as the proceeding looks toward several bellwether trials scheduled for 2014 and 2015.

Considering Filing a Georgia Byetta Lawsuit? Attorneys Can Answer Your Questions

If you or someone you love has been taking Byetta and you were diagnosed with thyroid cancer or pancreatic cancer, you may be entitled to file a Georgia Byetta lawsuit with the help of an experienced attorney. For answers to your questions or concerns, contact the Georgia Injury Attorney Group. We will provide you with a free case evaluation, determine if you are eligible to file claim and connect you with a professional attorney who will assist you in filing your Georgia Byetta lawsuit.

 

Comments